Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Decision On Arthritis Opens Door For Biosimilars

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

Executive Summary

A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

You may also be interested in...



How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Fresenius Kabi Concedes On FDA Pegfilgrastim Chances

Fresenius Kabi is continuing to suffer from the longstanding effects of the US FDA backlog for onsite inspection reviews amid the coronavirus pandemic. Management discussed Kabi’s latest prospects on its proposed pegfilgrastim biosimilar, as well as adalimumab and tocilizumab.

Biosimilars Industry Urges Improved UK Evaluation Process

A more efficient system to pave a path to market for biosimilars is needed in the UK, the British Biosimilars Association has urged, as it welcomed recent moves to broaden the use of adalimumab, etanercept and infliximab for treating moderate as well as severe rheumatoid arthritis.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel